UY27187A1 - Composiciones farmacéuticas - Google Patents

Composiciones farmacéuticas

Info

Publication number
UY27187A1
UY27187A1 UY27187A UY27187A UY27187A1 UY 27187 A1 UY27187 A1 UY 27187A1 UY 27187 A UY27187 A UY 27187A UY 27187 A UY27187 A UY 27187A UY 27187 A1 UY27187 A1 UY 27187A1
Authority
UY
Uruguay
Prior art keywords
pharmaceutical compositions
compositions
pravastatin
mammals
mammal
Prior art date
Application number
UY27187A
Other languages
English (en)
Inventor
Rene Belder
Mark E Mcgovern
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of UY27187A1 publication Critical patent/UY27187A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invención actual proporciona métodos y composiciones farmacéuticas para reducir los niveles de colesterol LDL en mamíferos, que comprende la administración de una cantidad terapéuticamente efectiva de más de 40mg una vez de pravastatina, o una sal o éster farmacéuticamente aceptable de la misma a un mamífero que necesita de dicho tratamiento.
UY27187A 2001-02-27 2002-02-27 Composiciones farmacéuticas UY27187A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/794,449 US20020183383A1 (en) 2001-02-27 2001-02-27 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
UY27187A1 true UY27187A1 (es) 2002-09-30

Family

ID=25162649

Family Applications (1)

Application Number Title Priority Date Filing Date
UY27187A UY27187A1 (es) 2001-02-27 2002-02-27 Composiciones farmacéuticas

Country Status (9)

Country Link
US (2) US20020183383A1 (es)
EP (1) EP1377277B1 (es)
AR (1) AR033424A1 (es)
AT (1) ATE403423T1 (es)
DE (1) DE60228064D1 (es)
ES (1) ES2309148T3 (es)
PE (1) PE20020893A1 (es)
UY (1) UY27187A1 (es)
WO (1) WO2002067911A1 (es)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5030447A (en) * 1988-03-31 1991-07-09 E. R. Squibb & Sons, Inc. Pharmaceutical compositions having good stability
US5180589A (en) * 1988-03-31 1993-01-19 E. R. Squibb & Sons, Inc. Pravastatin pharmaceuatical compositions having good stability
US5298497A (en) * 1990-05-15 1994-03-29 E. R. Squibb & Sons, Inc. Method for preventing onset of hypertension employing a cholesterol lowering drug
US5140012A (en) * 1990-05-31 1992-08-18 E. R. Squibb & Sons, Inc. Method for preventing onset of restenosis after angioplasty employing pravastatin
US5622985A (en) * 1990-06-11 1997-04-22 Bristol-Myers Squibb Company Method for preventing a second heart attack employing an HMG CoA reductase inhibitor
US5130333A (en) * 1990-10-19 1992-07-14 E. R. Squibb & Sons, Inc. Method for treating type II diabetes employing a cholesterol lowering drug
GB2253787A (en) * 1991-01-28 1992-09-23 Merck & Co Inc Hypercholesterolemia treating compositions
US6369103B1 (en) * 1994-01-18 2002-04-09 Bristol-Myers Squibb Company Method for preventing or reducing risk of onset of cardiovascular events employing an HMG CoA reductase inhibitor
KR20020063174A (ko) * 1999-11-03 2002-08-01 하워드 제이 스미스 앤드 어쏘시에이츠 피티와이 엘티디 간의 선택적 치료방법

Also Published As

Publication number Publication date
PE20020893A1 (es) 2002-10-25
US20030125379A1 (en) 2003-07-03
ATE403423T1 (de) 2008-08-15
ES2309148T3 (es) 2008-12-16
EP1377277B1 (en) 2008-08-06
EP1377277A1 (en) 2004-01-07
WO2002067911A1 (en) 2002-09-06
AR033424A1 (es) 2003-12-17
DE60228064D1 (de) 2008-09-18
US20020183383A1 (en) 2002-12-05

Similar Documents

Publication Publication Date Title
NO20065368L (no) Terapeutiske blandinger inneholdende minst et pyrrolobenzodiazepinderivat og fludarabin
DK1346041T3 (da) Terapeutiske midler og fremgangsmåder til anvendelse deraf til behandling af en amyloidogen sygdom
ECSP034603A (es) Combinaciones sinergicas que comprenden un inhibidor de renina para enfermedades cardiovasculares
ECSP034478A (es) Combinacion terapeutica
BRPI0520669A2 (pt) dosagem farmacêutica que reduz o efeito do alimento encontrado para administração de atorvastatina
BR0115109A (pt) Agentes terapêuticos e métodos de uso dos mesmos para a modulação da angiogênese
UY27586A1 (es) Cis- imidaxolinas
DK1257550T3 (da) Blodplade-ADP-receptor-inhibitor
BR0114526A (pt) Composições e métodos para reduzir as lipoproteinas(a) plasmáticas e os fatores de risco de doenças cardiovasculares
AR034900A1 (es) Uso de una cantidad eficaz de un inhibidor de pde4 y un agente anticolinergico, bien en forma combinada sola o por separado, composiciones farmaceuticas que los comprenden, metodo para prepararlas, y uso de una composicion que comprende una cantidad eficaz de un inhibidor de pde4, una cantidad efica
AR017514A1 (es) Composicion farmaceutica, una primera composicion para usarse como una segunda composicion, un estuche, procedimiento para tratar un mamifero
AR074313A1 (es) Metodo para tratar o prevenir la trombosis utilizando etexilato de dabigatran o una sal del mismo. uso. kit
PA8467401A1 (es) Procedimiento para tratar la insuficiencia cardiaca
GB0002336D0 (en) Medicaments
UY26163A1 (es) Sal mutua de amlodipino y atorvastatina
AR003589A1 (es) Utilizacion de una cantidad eficaz de al menos un peptido en una composicion cosmetica o para la preparacion de un medicamento destinada paratratar la inflamacion, y un procedimiento de tratamiento cosmetico mediante una composicion cosmetica que contiene a dicho peptido.
DK1296972T3 (da) Arylmethylamin-derivater til anvendelse som tryptaseinhibitorer
ES2164447T3 (es) Procedimiento de inhibicion de resorcion del hueso.
CO5570661A2 (es) Combinaciones que comprenden inhibidores de cox-2 y aspirina
ECSP055625A (es) Profarmaco inhibidor de beta-lactamasa
CO5200850A1 (es) Composicion farmaceutica para profilaxis y tratamiento de sintomas asociados con la gripa, influenza y enfermedades similares y procedimiento para su aplicacion
UY27187A1 (es) Composiciones farmacéuticas
AR039162A1 (es) Formulaciones de venlafaxina de liberacion extendida
ES2186153T3 (es) Sulfato de 5-alfa-pregnan-3-beta-ol-20-ona para el tratamiento de tumores y de los trastornos del snc.
CO5580773A2 (es) Rosuvastatina en estados pre dementes

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20141113